After new drug's ‘unprecedented' results for pancreatic cancer, doctors look at other uses

Chronological Source Flow
Back

AI Fusion Summary

Dr. Zev Wainberg led a phase 3 trial of 500 patients with advanced pancreatic cancer, where the experimental drug daraxonrasib doubled survival time. Patients chose the drug over failing chemotherapy, and none in the chemo arm survived.
Community Comments
Loading updates...
0